Dr. Katy Rezvani MD, PhD completed her medical training at University College London, followed by Fellowships of the Royal College of Physicians and the Royal College of Pathologists of the United Kingdom, a PhD in Immunology from Imperial College London and postdoctoral studies at the National Institutes of Health. She is the Sally Cooper Murray Chair in Cancer Research, Professor of Medicine, Chief of Section for Cellular Therapy, Director of Translational Research and Director of the GMP Facility at MD Anderson Cancer Center. She also serves as the Executive Director of the Adoptive Cell Therapy Platform at MD Anderson. Her research laboratory focuses on the role of natural killer (NK) cells in mediating immunity against hematologic and solid tumors. The goal of this research is to understand mechanisms of tumor-induced NK cell dysfunction and to develop strategies to genetically engineer NK cells in order to enhance their in vivo anti-tumor activity and persistence. Findings from Dr. Rezvani’s lab have led to the approval and funding of several investigator-initiated clinical trials of NK cell immunotherapy in patients with hematologic malignancies and solid tumors, as well as the first-in-human clinical trial of off-the-shelf CAR-transduced cord blood NK cells in patients with relapsed/refractory lymphoid malignancies. Dr. Rezvani’s work is supported by multiple grants from the National Cancer Institute, the Leukemia and Lymphoma Society, the American Cancer Society, Stand Up to Cancer and the Cancer Prevention & Research Institute of Texas (CPRIT).